2:11 PM
 | 
Jun 04, 2019
 |  BC Extra  |  Financial News

June 4 Financial Quick Takes: Lung Therapeutics' $36M series C; plus Strand, Hansoh, Inhibrx and more

Lung Therapeutics closes $36M series C
Lung Therapeutics Inc. (Austin, Texas) raised $36 million in a series C round led by Bios Partners with participation by undisclosed new and existing investors. Lung has raised $53 million to date. The company plans to begin in 4Q19 a Phase II trial of lead compound, LTI-01, in pneumonia patients with loculated pleural effusions and a Phase I trial of non-fibrinolytic peptide LTI-03 in idiopathic pulmonary fibrosis. LTI-01 is a single-chain urokinase plasminogen activator, and LTI-03's mechanism of action is undisclosed...

Read the full 407 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >